ECONOMIC AND HUMANISTIC BURDEN AMONG U.S. ADULTS WITH NONHODGKIN LYMPHOMA: ANALYSIS OF NATIONAL SURVEY DATA
Author(s)
Qian Ding, PhD1, Claire Saadeh, PharmD2, Shruti Patel, PharmD Candidate3, Mitchell Castanon, PharmD Candidate4;
1Ferris State University, Associate Professor, Big Rapids, MI, USA, 2Ferris State University, Grand Rapids, MI, USA, 3Thomas Jefferson University, Philadelphia, PA, USA, 4The Western New England University, Springfield, MA, USA
1Ferris State University, Associate Professor, Big Rapids, MI, USA, 2Ferris State University, Grand Rapids, MI, USA, 3Thomas Jefferson University, Philadelphia, PA, USA, 4The Western New England University, Springfield, MA, USA
OBJECTIVES: To compare health care expenditures and health-related quality of life (HRQoL) between adults with non-Hodgkin lymphoma (NHL) and those with other rare cancers, including Leukemia, Pancreas, brain, and bone cancer, using nationally representative data.
METHODS: A cross-sectional analysis of the 2022 Medical Expenditure Panel Survey (MEPS) was conducted. Adults older than 18 years with self-reported cancer (CANCERDX) were classified as having NHL if they reported lymphoma (CALYMPH=1). Patients who reported rare cancer but reported not NHL (CALYMPH=2 and CAOTHER=1) served as a comparison group. Total and out-of-pocket (OOP) expenditures were aggregated across prescribed medicines, inpatient, emergency, outpatient/ambulatory, office-based, home health, and other medical event files. The HRQoL was assessed using VR-12 physical and Mental component items, two-week PHQ-2 items, and 30-day nonspecific psychological distress items.
RESULTS: A total of 67 NHL patients were identified, representing approximately 854,884 U.S. adults in 2022. The rare cancer group included 426 patients (weighted n=5,191,336). NHL patients were slightly younger (mean age=57.6 vs. 59.2 years). There was no statistically significant difference in unadjusted total annual healthcare expenditures between the rare cancer and NHL groups ($20,935 vs. $12,788; P=0.087). VR-12 scores were similar low between groups (PCS: 32.1 vs. 29.6; MCS: 37.6 vs. 34.2), indicating compromised physical and mental health. Approximately 30% of NHL patients reported limitations in moderate activities, difficulty climbing stairs, work limitations due to physical health, and pain interfering with normal activities. In addition, over 40% of the NHL patients reported felt downhearted and blue over the past four weeks.
CONCLUSIONS: The U.S. nonHodgkin Lymphoma patients experienced high healthcare utilization and impaired physical and mental health.These findings indicate the need for targeted supportive care and survivorship interventions to improve outcomes among individuals living with NHL.
METHODS: A cross-sectional analysis of the 2022 Medical Expenditure Panel Survey (MEPS) was conducted. Adults older than 18 years with self-reported cancer (CANCERDX) were classified as having NHL if they reported lymphoma (CALYMPH=1). Patients who reported rare cancer but reported not NHL (CALYMPH=2 and CAOTHER=1) served as a comparison group. Total and out-of-pocket (OOP) expenditures were aggregated across prescribed medicines, inpatient, emergency, outpatient/ambulatory, office-based, home health, and other medical event files. The HRQoL was assessed using VR-12 physical and Mental component items, two-week PHQ-2 items, and 30-day nonspecific psychological distress items.
RESULTS: A total of 67 NHL patients were identified, representing approximately 854,884 U.S. adults in 2022. The rare cancer group included 426 patients (weighted n=5,191,336). NHL patients were slightly younger (mean age=57.6 vs. 59.2 years). There was no statistically significant difference in unadjusted total annual healthcare expenditures between the rare cancer and NHL groups ($20,935 vs. $12,788; P=0.087). VR-12 scores were similar low between groups (PCS: 32.1 vs. 29.6; MCS: 37.6 vs. 34.2), indicating compromised physical and mental health. Approximately 30% of NHL patients reported limitations in moderate activities, difficulty climbing stairs, work limitations due to physical health, and pain interfering with normal activities. In addition, over 40% of the NHL patients reported felt downhearted and blue over the past four weeks.
CONCLUSIONS: The U.S. nonHodgkin Lymphoma patients experienced high healthcare utilization and impaired physical and mental health.These findings indicate the need for targeted supportive care and survivorship interventions to improve outcomes among individuals living with NHL.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EPH29
Topic
Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology